Linklaters advises Ab&B Bio-Tech on its HKEX IPO

Linklaters acted as the Hong Kong and US counsel for Ab&B Bio-Tech CO., LTD. JS (Ab&B Bio-Tech) on its global offering and listing of H shares on the Main Board of the Hong Kong Stock Exchange (HKEX) under Chapter 18A of the Hong Kong Listing Rules. The Hong Kong public offering was oversubscribed by over 4,000 times, making it one of the most popular new listings this year.

Founded in 2015, Ab&B Bio-Tech is a China-based vaccine company dedicated to the research, development, manufacturing and commercialisation of innovative vaccines and traditional vaccines adopting new technical methods.

The Linklaters team was led by partner and Head of Greater China ECM Christine Xu, capital markets partner Lipton Li and Special Senior Adviser and New Economy Team Leader (Greater China) Oliver Zhong, with support from corporate counsel Queenie Tong.

Partner and Head of Greater China ECM Christine Xu commented:

“Many congratulations to Ab&B Bio-Tech on this successful IPO! This transaction underscores the continued attractiveness of Hong Kong SAR as a listing destination and showcases Linklaters’ depth of expertise in advising fast-growing, innovative biotech companies on capital raising from public markets including achieving transformative milestones such as IPOs.”

Linklaters’ highly experienced Greater China ECM team provides seamless legal support on pre-IPO investments, IPOs, post-listing compliance and post-IPO equity financing, including advising on the recent HKEX IPOs of CATL, Sanhua Intelligent and FWD Group, as well as share placings for Innovent Biologics, Keymed Biosciences, Minieye Technology and RoboSense.